Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer

The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy

(2011) Nazanin Fallah-Rad et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer

(2010) R. B. Costa et al.   ANNALS OF ONCOLOGY

Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer

(2010) Fausto Petrelli et al.   ANTI-CANCER DRUGS

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis

(2010) Tao Chen et al.   CANCER TREATMENT REVIEWS

First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

(2010) Marion Procter et al.   JOURNAL OF CLINICAL ONCOLOGY

Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials

(2010) Stuart D. Russell et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Heart Failure With Normal Ejection Fraction: The Complementary Roles of Echocardiography and CMR Imaging

(2010) Darryl P. Leong et al.   JACC-Cardiovascular Imaging

Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab

(2009) James L. Hare et al.   AMERICAN HEART JOURNAL

Never use anthracyclines with trastuzumab: it is time to reconsider the taboo

(2009) Luca Gianni   BREAST CANCER RESEARCH AND TREATMENT

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

(2009) A L Jones et al.   BRITISH JOURNAL OF CANCER

Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study

(2009) Maya Guglin et al.   JOURNAL OF CARDIAC FAILURE

Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations

(2009) M. Martin et al.   ONCOLOGIST

Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study

(2008) Deepa Wadhwa et al.   BREAST CANCER RESEARCH AND TREATMENT

EANM/ESC guidelines for radionuclide imaging of cardiac function

(2008) B. Hesse et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Unlocking the Mysteries of Diastolic Function

(2008) Steven J. Lester et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Monitoring of Anthracycline-Induced Cardiotoxicity

(2007) Abigail Jannazzo et al.   ANNALS OF PHARMACOTHERAPY